ストックスクリーナーアプリを入手
0.1581
6.75%
0.010
プレマーケット:
.15
-0.0081
-5.12%
前日終値:
$0.1481
開ける：
$0.1488
24時間の取引高:
894.08K
Relative Volume:
0.39
時価総額：
$13.10M
収益：
$11.00M
当期純損益:
$-64.71M
株価収益率:
-0.1375
EPS:
-1.1496
ネットキャッシュフロー:
$-57.52M
1週間 パフォーマンス:
-1.19%
1か月 パフォーマンス:
-17.31%
6か月 パフォーマンス:
-74.90%
1年 パフォーマンス:
-56.92%
1日の値動き範囲:
$0.1488
$0.1664
1週間の範囲:
$0.148
$0.178
52週間の値動き範囲:
$0.13
$1.43
Bioatla Inc Stock (BCAB) Company Profile
Compare BCAB vs VRTX, REGN, ALNY, ARGX, INSM
| 株式 | 価格 | 時価総額 | 収益 | 当期純利益 | 現金流量 | EPS |
|---|---|---|---|---|---|---|
BCAB
Bioatla Inc
|
0.1581 | 13.10M | 11.00M | -64.71M | -57.52M | -1.1496 |
VRTX
Vertex Pharmaceuticals Inc
|
454.97 | 115.58B | 12.07B | 3.95B | 3.19B | 15.33 |
REGN
Regeneron Pharmaceuticals Inc
|
749.47 | 79.23B | 14.34B | 4.50B | 3.77B | 41.56 |
ALNY
Alnylam Pharmaceuticals Inc
|
328.70 | 43.59B | 3.71B | 313.75M | 465.38M | 2.2571 |
ARGX
Argen X Se Adr
|
697.05 | 43.26B | 4.16B | 1.29B | 734.26M | 19.58 |
INSM
Insmed Inc
|
148.31 | 31.97B | 606.42M | -1.28B | -997.58M | -6.403 |
Bioatla Inc Stock (BCAB) Upgrades & Downgrades
| 日付 | アクション | アナリスト | 評価の変更 |
|---|---|---|---|
| 2026-01-13 | 開始されました | Rodman & Renshaw | Buy |
| 2025-08-13 | ダウングレード | Citizens JMP | Mkt Outperform → Mkt Perform |
| 2024-11-13 | ダウングレード | H.C. Wainwright | Buy → Neutral |
| 2022-09-15 | 開始されました | JMP Securities | Mkt Outperform |
| 2022-05-05 | ダウングレード | Credit Suisse | Outperform → Neutral |
| 2022-03-21 | 開始されました | H.C. Wainwright | Buy |
| 2021-10-15 | 再開されました | BTIG Research | Buy |
| 2021-06-28 | 開始されました | ROTH Capital | Buy |
| 2021-05-05 | 再開されました | Credit Suisse | Outperform |
| 2021-04-26 | 再開されました | Credit Suisse | Outperform |
| 2021-01-11 | 開始されました | BTIG Research | Buy |
| 2021-01-11 | 開始されました | Credit Suisse | Outperform |
| 2021-01-11 | 開始されました | JP Morgan | Overweight |
| 2021-01-11 | 開始されました | Jefferies | Buy |
すべてを表示
Bioatla Inc (BCAB) 最新ニュース
Buyout Rumor: Can BioAtla Inc deliver consistent dividends2026 Decliners & Risk Managed Investment Signals - baoquankhu1.vn
BioAtla, Inc. 8-K SEC Filing March 17, 2026: Company Information, Key Details, and Legal Disclosures - Minichart
BioAtla Shareholders Approve Merger and Share Consolidation - TipRanks
BioAtla (NASDAQ: BCAB) approves merger, 1-for-50 reverse split and 2026 executive retention bonuses - Stock Titan
842,440 shares issued to YA II PN, Ltd.; BioAtla (NASDAQ: BCAB) registers resale - Stock Titan
BCAB Stock Price, Quote & Chart | BIOATLA INC (NASDAQ:BCAB) - ChartMill
Breakout Watch: What is the dividend yield of BioAtla IncEarnings Growth Summary & Technical Buy Zone Confirmation - baoquankhu1.vn
BCAB Technical Analysis | Trend, Signals & Chart Patterns | BIOATLA INC (NASDAQ:BCAB) - ChartMill
BioAtla (NASDAQ: BCAB) to issue 631,163 shares to Yorkville under SEPA - Stock Titan
BioAtla (NASDAQ: BCAB) CMO receives 240,000-share time-based RSU award - Stock Titan
BioAtla (NASDAQ: BCAB) CEO receives 430,000-share RSU grant - Stock Titan
BioAtla (BCAB) CFO awarded 240,000 restricted stock units, total holdings 530,196 shares - Stock Titan
12 Health Care Stocks Moving In Tuesday's Pre-Market Session - Benzinga
Published on: 2026-03-07 14:29:43 - Naître et grandir
BioAtla launches major restructuring and leadership transition - The Globe and Mail
BioAtla explores sale as it cuts 70% of workforce - Investing.com South Africa
BioAtla (BCAB) CFO sees 1,802 shares withheld for RSU tax settlement - Stock Titan
[Form 4] BioAtla, Inc. Insider Trading Activity - Stock Titan
BioAtla (BCAB) CMO reports 3,140-share tax withholding on RSU vesting - Stock Titan
BioAtla explores sale as it cuts 70% of workforce By Investing.com - Investing.com India
BioAtla, Inc. Initiates Strategic Review Process and Workforce Restructuring to Enhance Shareholder Value - Quiver Quantitative
BioAtla Inc announces 70% workforce reductionSEC filing - marketscreener.com
BioAtla appoints Chris Vasquez as CFO as Richard Waldron departs - TradingView
BioAtla (NASDAQ: BCAB) slashes workforce 70% amid strategic review, listing risk - Stock Titan
BioAtla, Inc. Implements Workforce Reduction of Approximately 70% - marketscreener.com
Bioatla announces formal process to evaluate strategic options to monetize assets - marketscreener.com
Bioatla Announces Formal Process To Evaluate Strategic Options To Monetize Assets - TradingView
Biotech BioAtla to shed 70% of staff while weighing asset sales - Stock Titan
Bioatla, Inc. Announces CFO Changes. Effective March 2, 2026 - marketscreener.com
BCAB PE Ratio & Valuation, Is BCAB Overvalued - Intellectia AI
US Market Wrap: Does BioAtla Inc meet Warren Buffetts criteria2025 Retail Activity & Low Drawdown Momentum Ideas - baoquankhu1.vn
Aug Sentiment: Is BioAtla Inc forming bullish engulfing patterns2025 Geopolitical Influence & Long-Term Safe Return Strategies - baoquankhu1.vn
BioAtla, Inc. (NASDAQ:BCAB) Sees Large Drop in Short Interest - Defense World
BioAtla (BCAB) CEO has shares withheld to cover RSU taxes - Stock Titan
12 Health Care Stocks Moving In Friday's Pre-Market Session - Benzinga
BioAtla to Participate in the Citizens Life Sciences Conference - 富途牛牛
Gap Down: Will BioAtla Inc stock hit new highs in YEAR2025 Bull vs Bear & Accurate Intraday Trading Signals - baoquankhu1.vn
BCABBioatla, Inc. Latest Stock News & Market Updates - Stock Titan
12 Health Care Stocks Moving In Thursday's After-Market Session - Benzinga
Aug Chart Watch: Will Nixxy Inc Equity Warrant outperform its industry peers2025 Trading Volume Trends & Accurate Buy Signal Alerts - baoquankhu1.vn
Why BioAtla Inc. stock is popular among millennials2025 Pullback Review & Entry and Exit Point Strategies - mfd.ru
What analysts say about BioAtla Inc. stockJuly 2025 Review & Growth Focused Stock Reports - mfd.ru
BCAB Should I Buy - Intellectia AI
BioAtla Sets March Virtual Vote on Internal Merger Plan - The Globe and Mail
Why BioAtla Inc. stock could see breakout soonSell Signal & Community Consensus Picks - mfd.ru
BioAtla (BCAB) seeks approval for 1‑for‑50 share conversion to support Nasdaq listing - Stock Titan
Bioatla Faces Nasdaq Delisting Review Amid Corporate Restructuring - AD HOC NEWS
Is BioAtla Inc. currently under institutional pressureQuarterly Risk Review & Technical Analysis for Trade Confirmation - mfd.ru
BioAtla Faces Nasdaq Review of Continued Listing Status - The Globe and Mail
BioAtla to remain on Nasdaq during listing council review process By Investing.com - Investing.com Canada
BioAtla to remain on Nasdaq during listing council review process - Investing.com Nigeria
Bioatla Inc (BCAB) 財務データ
収益
当期純利益
現金流量
EPS
1.82%
大文字化:
|
ボリューム (24 時間):